GlassScriptPhysician profile
Ashley Larsen
NPI 1144301458
$10,626.08
in general payments reported to CMS, 2019-2025
42 companies · $3,261 in 2025
The $3,261 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,526 · 2022: $1,872 · 2023: $2,111 · 2024: $1,856 · 2025: $3,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,443 · Travel and Lodging: $685 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,442.88 |
| Travel and Lodging | $685.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,566.87 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $1,123.28 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,052.14 | 2021-2025 | Tezspire, Fasenra, Andexxa |
| Actelion Pharmaceuticals US, INC. | $969.81 | 2021-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $882.99 | 2021-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $651.48 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $488.67 | 2021-2025 | Glassia |
| Genzyme Corporation | $414.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $332.91 | 2021-2025 | Keytruda, Winrevair |
| Mylan Specialty L.P. | $272.09 | 2021-2024 | Yupelri |
| Electromed, INC. | $247.42 | 2021-2025 | Smartvest |
| Amgen INC. | $243.61 | 2022-2024 | Evenity, Prolia, Tezspire |
| Mallinckrodt Hospital Products INC. | $230.55 | 2021-2025 | Acthar |
| Grifols USA, LLC | $209.89 | 2021-2022 | |
| Verona Pharma, INC. | $204.22 | 2025 | Ohtuvayre |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $174.98 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $161.91 | 2021-2023 | |
| Baxter Healthcare | $158.23 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $149.61 | 2022-2025 | |
| Genentech USA, INC. | $123.88 | 2021-2023 | Xolair, Esbriet |
| Viatris Specialty LLC | $121.03 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $93.88 | 2023 | Ultomiris, Strensiq |
| Insmed, INC. | $92.45 | 2021-2023 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $78.32 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $69.79 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $63.54 | 2024-2025 | Cresemba |
| Philips North America LLC | $60.62 | 2023-2025 | Vest Therapy Und |
| Jazz Pharmaceuticals INC. | $55.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.65 | 2022-2023 | |
| La Jolla Pharmaceutical Company | $39.59 | 2024-2025 | Giapreza |
| Xeris Pharmaceuticals, INC. | $36.90 | 2025 | Recorlev |
| Alnylam Pharmaceuticals INC. | $29.08 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.87 | 2022 | |
| Lungpacer Medical USA INC | $27.21 | 2025 | Aeropace Neurostimulation Console |
| Amryt Pharma Holdings LTD | $24.50 | 2023 | Mycapssa |
| Pfizer INC. | $19.21 | 2024 | |
| Novo Nordisk INC | $18.48 | 2024 | Ozempic |
| Advanced Respiratory, INC | $15.00 | 2021 | |
| Apria Healthcare LLC | $14.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2021 | |
| Gilead Sciences, INC. | $13.85 | 2021 | |
| Ambu INC. | $9.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.